Denise C Hegan
Overview
Explore the profile of Denise C Hegan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scanlon S, Hegan D, Sulkowski P, Glazer P
Oncotarget
. 2018 Feb;
9(4):4647-4660.
PMID: 29435132
The von Hippel-Lindau () tumor suppressor gene is inactivated in the vast majority of human clear cell renal carcinomas. The pathogenesis of loss is currently best understood to occur through...
2.
Turchick A, Hegan D, Jensen R, Glazer P
Nucleic Acids Res
. 2017 Oct;
45(20):11782-11799.
PMID: 29036688
RAD51, a key factor in homology-directed repair (HDR), has long been considered an attractive target for cancer therapy, but few specific inhibitors have been found. A cell-penetrating, anti-DNA, lupus autoantibody,...
3.
Scanlon S, Scanlon C, Hegan D, Sulkowski P, Glazer P
Carcinogenesis
. 2017 May;
38(6):627-637.
PMID: 28472268
The heavy metal nickel is a known carcinogen, and occupational exposure to nickel compounds has been implicated in human lung and nasal cancers. Unlike many other environmental carcinogens, however, nickel...
4.
Sulkowski P, Corso C, Robinson N, Scanlon S, Purshouse K, Bai H, et al.
Sci Transl Med
. 2017 Feb;
9(375).
PMID: 28148839
2-Hydroxyglutarate (2HG) exists as two enantiomers, (R)-2HG and (S)-2HG, and both are implicated in tumor progression via their inhibitory effects on α-ketoglutarate (αKG)-dependent dioxygenases. The former is an oncometabolite that...
5.
Colis L, Hegan D, Kaneko M, Glazer P, Herzon S
J Am Chem Soc
. 2015 Apr;
137(17):5741-7.
PMID: 25849366
(-)-Lomaiviticin A (1) and the monomeric lomaiviticin aglycon [aka: (-)-MK7-206, (3)] are cytotoxic agents that induce double-strand breaks (DSBs) in DNA. Here we elucidate the cellular responses to these agents...
6.
Colis L, Woo C, Hegan D, Li Z, Glazer P, Herzon S
Nat Chem
. 2014 May;
6(6):504-10.
PMID: 24848236
The metabolite (-)-lomaiviticin A, which contains two diazotetrahydrobenzo[b]fluorene (diazofluorene) functional groups, inhibits the growth of cultured human cancer cells at nanomolar-picomolar concentrations; however, the mechanism responsible for the potent cytotoxicity...
7.
Glazer P, Hegan D, Lu Y, Czochor J, Scanlon S
Yale J Biol Med
. 2013 Dec;
86(4):443-51.
PMID: 24348208
Hypoxia is a characteristic feature of solid tumors and occurs very early in neoplastic development. Hypoxia transforms cell physiology in multiple ways, with profound changes in cell metabolism, cell growth,...
8.
Hansen J, Chan G, Liu Y, Hegan D, Dalal S, Dray E, et al.
Sci Transl Med
. 2012 Oct;
4(157):157ra142.
PMID: 23100628
Systemic lupus erythematosus (SLE) is distinct among autoimmune diseases because of its association with circulating autoantibodies reactive against host DNA. The precise role that anti-DNA antibodies play in SLE pathophysiology...
9.
Rogers F, Lin S, Hegan D, Krause D, Glazer P
Mol Ther
. 2011 Aug;
20(1):109-18.
PMID: 21829173
Hematopoietic stem cell (HSC) gene therapy offers promise for the development of new treatments for a variety of hematologic disorders. However, efficient in vivo modification of HSCs has proved challenging,...
10.
Knauert M, Kalish J, Hegan D, Glazer P
Mol Ther
. 2006 May;
14(3):392-400.
PMID: 16731047
Gene targeting via homologous recombination offers a potential strategy for therapeutic correction of mutations in disease-related human genes. However, there is a need to improve the efficiency of site-specific recombination...